Jennifer O’nEill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer O’nEill has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Sara Hurtado Bares
Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska
4 shared publications - Jennifer M Davis
Division of Infectious Diseases, University of Nebraska Medical Center , Omaha, Nebraska
3 shared publications - Joshua P. Havens
College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska
2 shared publications Maureen Kubat
Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska
2 shared publications- Mikki Schantell
Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, NE, USA
2 shared publications - Shawnalyn W. Sunagawa
University of Nebraska Medical Center
2 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery
Long-acting injectable cabotegravir plus rilpivirine offers an alternative to daily oral antiretroviral therapy, but insurance-related barriers can disrupt implementation. We examined the frequency and impact of insurance changes in a United States cohort and found that nearly half of patients experienced insurance changes, which could lead to delayed injections.
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessReal-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery
Long-acting injectable cabotegravir plus rilpivirine offers an alternative to daily oral antiretroviral therapy, but insurance-related barriers can disrupt implementation. We examined the frequency and impact of insurance changes in a United States cohort and found that nearly half of patients experienced insurance changes, which could lead to delayed injections.
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Scalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program
Implementation of a long-acting injectable antiretroviral treatment program requires substantial multidisciplinary effort, particularly for program coordination, coverage/billing, and patient support/retention. As our program scaled to 113 patients over 2.5 years, a total of 2.25 full-time equivalents were required. Despite operational demands, clinical outcomes were favorable, supporting real-world feasibility and scalability.
- 3 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Open AccessScalability Metrics and Effort Requirements for a Long-Acting Injectable Antiretroviral Treatment Program
Implementation of a long-acting injectable antiretroviral treatment program requires substantial multidisciplinary effort, particularly for program coordination, coverage/billing, and patient support/retention. As our program scaled to 113 patients over 2.5 years, a total of 2.25 full-time equivalents were required. Despite operational demands, clinical outcomes were favorable, supporting real-world feasibility and scalability.
- Open Access
- 30 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf399
Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report
Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case of sustained virologic suppression 18 months after discontinuation of long-acting cabotegravir/rilpivirine despite inadequate adherence to oral antiretroviral therapy.
- 30 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf399
Open AccessSustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report
Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case of sustained virologic suppression 18 months after discontinuation of long-acting cabotegravir/rilpivirine despite inadequate adherence to oral antiretroviral therapy.
- Open Access
- 15 December 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (24) , 9818-9831
Epigenetic aging is associated with aberrant neural oscillatory dynamics serving visuospatial processing in people with HIV
Background: Despite effective antiretroviral therapy, cognitive impairment and other aging-related comorbidities are more prevalent in people with HIV (PWH) than in the general population. Previous research examining DNA methylation has shown PWH exhibit accelerated biological aging. However, it is unclear how accelerated biological aging may affect neural oscillatory activity in virally suppressed PWH, and more broadly how such aberrant neural activity may impact neuropsychological performance. Methods: In the present study, participants (n = 134) between the ages of 23 – 72 years underwent a neuropsychological assessment, a blood draw to determine biological age via DNA methylation, and a visuospatial processing task during magnetoencephalography (MEG). Our analyses focused on the relationship between biological age and oscillatory theta (4-8 Hz) and alpha (10 - 16 Hz) activity among PWH (n=65) and seronegative controls (n = 69). Results: PWH had significantly elevated biological age when controlling for chronological age relative to controls. Biological age was differentially associated with theta oscillations in the left posterior cingulate cortex (PCC) and with alpha oscillations in the right medial prefrontal cortex (mPFC) among PWH and seronegative controls. Stronger alpha oscillations in the mPFC were associated with lower CD4 nadir and lower current CD4 counts, suggesting such responses were compensatory. Participants who were on combination antiretroviral therapy for longer had weaker theta oscillations in the PCC. Conclusions: These findings support the concept of interactions between biological aging and HIV status on the neural oscillatory dynamics serving visuospatial processing. Future work should elucidate the long-term trajectory and impact of accelerated aging on neural oscillatory dynamics in PWH.
- 15 December 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (24) , 9818-9831
Open AccessEpigenetic aging is associated with aberrant neural oscillatory dynamics serving visuospatial processing in people with HIV
Background: Despite effective antiretroviral therapy, cognitive impairment and other aging-related comorbidities are more prevalent in people with HIV (PWH) than in the general population. Previous research examining DNA methylation has shown PWH exhibit accelerated biological aging. However, it is unclear how accelerated biological aging may affect neural oscillatory activity in virally suppressed PWH, and more broadly how such aberrant neural activity may impact neuropsychological performance. Methods: In the present study, participants (n = 134) between the ages of 23 – 72 years underwent a neuropsychological assessment, a blood draw to determine biological age via DNA methylation, and a visuospatial processing task during magnetoencephalography (MEG). Our analyses focused on the relationship between biological age and oscillatory theta (4-8 Hz) and alpha (10 - 16 Hz) activity among PWH (n=65) and seronegative controls (n = 69). Results: PWH had significantly elevated biological age when controlling for chronological age relative to controls. Biological age was differentially associated with theta oscillations in the left posterior cingulate cortex (PCC) and with alpha oscillations in the right medial prefrontal cortex (mPFC) among PWH and seronegative controls. Stronger alpha oscillations in the mPFC were associated with lower CD4 nadir and lower current CD4 counts, suggesting such responses were compensatory. Participants who were on combination antiretroviral therapy for longer had weaker theta oscillations in the PCC. Conclusions: These findings support the concept of interactions between biological aging and HIV status on the neural oscillatory dynamics serving visuospatial processing. Future work should elucidate the long-term trajectory and impact of accelerated aging on neural oscillatory dynamics in PWH.
- 19 July 2022
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 33 (6) , 3181-3192
Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer’s disease
Adults with HIV frequently develop a form of mild cognitive impairment known as HIV-associated neurocognitive disorder (HAND), but presumably cognitive decline in older persons with HIV could also be attributable to Alzheimer’s disease (AD). However, distinguishing these two conditions in individual patients is exceedingly difficult, as the distinct neural and neuropsychological features are poorly understood and most studies to date have only investigated HAND or AD spectrum (ADS) disorders in isolation. The current study examined the neural dynamics underlying visuospatial processing using magnetoencephalography (MEG) in 31 biomarker-confirmed patients on the ADS, 26 older participants who met criteria for HAND, and 31 older cognitively normal controls. MEG data were examined in the time–frequency domain, and a data-driven approach was utilized to identify the neural dynamics underlying visuospatial processing. Both clinical groups (ADS/HAND) were significantly less accurate than controls on the task and exhibited stronger prefrontal theta oscillations compared to controls. Regarding disease-specific alterations, those with HAND exhibited stronger alpha oscillations than those on the ADS in frontoparietal and temporal cortices. These results indicate both common and unique neurophysiological alterations among those with ADS disorders and HAND in regions serving visuospatial processing and suggest the underlying neuropathological features are at least partially distinct.
- 19 July 2022
- Published by Oxford University Press (OUP) in Cerebral Cortex
- Vol. 33 (6) , 3181-3192
Convergent and divergent oscillatory aberrations during visuospatial processing in HIV-related cognitive impairment and Alzheimer’s disease
Adults with HIV frequently develop a form of mild cognitive impairment known as HIV-associated neurocognitive disorder (HAND), but presumably cognitive decline in older persons with HIV could also be attributable to Alzheimer’s disease (AD). However, distinguishing these two conditions in individual patients is exceedingly difficult, as the distinct neural and neuropsychological features are poorly understood and most studies to date have only investigated HAND or AD spectrum (ADS) disorders in isolation. The current study examined the neural dynamics underlying visuospatial processing using magnetoencephalography (MEG) in 31 biomarker-confirmed patients on the ADS, 26 older participants who met criteria for HAND, and 31 older cognitively normal controls. MEG data were examined in the time–frequency domain, and a data-driven approach was utilized to identify the neural dynamics underlying visuospatial processing. Both clinical groups (ADS/HAND) were significantly less accurate than controls on the task and exhibited stronger prefrontal theta oscillations compared to controls. Regarding disease-specific alterations, those with HAND exhibited stronger alpha oscillations than those on the ADS in frontoparietal and temporal cortices. These results indicate both common and unique neurophysiological alterations among those with ADS disorders and HAND in regions serving visuospatial processing and suggest the underlying neuropathological features are at least partially distinct.